results: among the colorectal cancer cell lines, five with a kras mutation (lovo, hct116, hct15, sw620, and sw480) and one with a braf mutation (ht29) were resistant to the antiproliferative effects of cetuximab, whereas two cells (geo and sw48) were highly sensitive.